BMPR2 production promoter
A composition containing ε-aminocaproic acid and/or its salts effectively promotes BMPR2 production, addressing the need for a pulmonary arterial hypertension improving agent.
Patent Information
- Application Number
- JP2020206941
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-12-14
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-12-14
AI Technical Summary
There is a lack of a pharmaceutical composition that effectively promotes BMPR2 expression and improves pulmonary arterial hypertension, which is characterized by containing ε-aminocaproic acid as an active ingredient.
A composition comprising ε-aminocaproic acid and/or its salts is developed to promote BMPR2 production, thereby improving pulmonary arterial hypertension.
The composition safely and effectively promotes BMPR2 production, demonstrating significant improvement in pulmonary arterial hypertension symptoms.
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent for promoting BMPR2 production and an agent for improving pulmonary arterial hypertension, which are characterized by containing ε-aminocaproic acid and / or a salt thereof. [Background technology]
[0002] Bone morphogenetic proteins (BMPs) are known to be involved in the process of differentiation of pluripotent mesenchymal stem cells into osteoblasts, as well as in mineralization and bone formation. BMPs belong to the transforming growth factor-β (TGF-β) superfamily, and 14 ligands (BMP2, BMP4, BMP7, etc.) and two receptors (BMPR1, BMPR2) have been identified (Non-Patent Documents 1 and 2). In addition to cell differentiation and bone formation, the physiological functions of BMPs are diverse, including their involvement as regulators in cell proliferation, organogenesis, organogenesis, and apoptosis (Non-Patent Document 3).
[0003] Pulmonary arterial hypertension is a condition in which the pressure (blood pressure) of the pulmonary artery, which is a blood vessel that sends blood from the heart to the lungs, rises abnormally. The rise in pulmonary arterial pressure occurs when the small blood vessels in the lungs become abnormally narrow and hard, which impairs blood flow (Non-Patent Document 4). As the disease progresses and pulmonary vascular resistance increases, cardiac output restriction during exercise appears. As the disease progresses further, cardiac output at rest also decreases, and right ventricular hypertrophy occurs due to persistent and progressive right ventricular load, but in some cases, appropriate hypertrophy is not accompanied, and in some cases, right heart failure occurs due to acute exacerbation. Pulmonary arterial hypertension corresponds to Group I in the Nice classification, and is composed of sudden and hereditary, collagen disease, congenital heart disease, portal hypertension, and other diseases (Non-Patent Document 5). However, the causes of onset in most pathological conditions have not been elucidated, and it is designated as an intractable disease.
[0004] Pulmonary arterial hypertension without underlying disease may occur in families, and mutations in the BMPR2 gene and associated functional impairment have been identified as causative genes (Non-Patent Documents 5, 6, 7, 8). In addition, methods for preventing and treating pulmonary arterial hypertension have been known, including therapy using BMPR2 activators (Patent Document 1) and peptides specific to the lungs (Patent Document 2). Therefore, enhancing the expression of BMPR2 and normalizing its function is thought to lead to improvement of symptoms.
[0005] ε-Aminocaproic acid is an aminocarboxylic acid type anti-inflammatory agent that suppresses the production of inflammatory inducers such as plasmin produced in the body (Patent Document 3). To date, aggregates containing ε-aminocaproic acid as a thrombus-forming agent (Patent Document 4), compositions containing ε-aminocaproic acid as a drug for regulating angiogenesis (Patent Document 5), and the like are known. However, no BMPR2 production promoters or pulmonary arterial hypertension ameliorators characterized by containing ε-aminocaproic acid as an active ingredient are known. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Special table 2018-502126 [Patent Document 2] Patent Publication No. 2019-214579 [Patent Document 3] Patent Publication No. 2006-182655 [Patent Document 4] Special table 2013-536848 [Patent Document 5] Patent Publication No. 2014-205697 [Non-patent literature]
[0007] [Non-Patent Document 1] Shizuka Yamada, Biomedical Engineering, 44(4), 490-495(2006) [Non-Patent Document 2] Yuji Mishina, Biochemistry, 89(3), 400-413(2017) [Non-Patent Document 3] Masatake Izumi, Journal of Dental Science, 102(10), 764-771(2002) [Non-Patent Document 4] Intractable Disease Information Center, Pulmonary arterial hypertension (designated intractable disease 86) [Non-Patent Document 5] Nobuhiro Tanabe, Journal of the Japanese Society of Internal Medicine, 103(9), 2137-2143(2014) [Non-Patent Document 6] Am.J.Hum.Genet.,67(3),737-744(2000) [Non-Patent Document 7] Nat Genet.,26(1),81-84(2000) [Non-Patent Document 8] Am.J.Hum.Genet.,68(1),92-102(2001) Summary of the Invention [Problem to be solved by the invention]
[0008] The problem to be solved by the present invention is to find a pharmaceutical composition that promotes BMPR2 expression, and to provide an excellent BMPR2 production promoter and pulmonary arterial hypertension ameliorator that contains this as an active ingredient and has a clear mode of action. [Means for solving the problem]
[0009] As a result of intensive research aimed at solving the above problems, the present inventors have found that ε-aminocaproic acid and / or a salt thereof has an excellent effect of promoting BMPR2 production. Furthermore, the present inventors have found that a composition containing ε-aminocaproic acid and / or a salt thereof has an excellent effect of improving pulmonary arterial hypertension, and have completed the present invention.
[0010] Specifically, the present invention relates to an agent for promoting BMPR2 production and an agent for improving pulmonary arterial hypertension, which are characterized by containing ε-aminocaproic acid and / or a salt thereof as an active ingredient.
[0011] The present invention includes the following inventions. (1) A BMPR2 production promoter comprising ε-aminocaproic acid and / or a salt thereof. (2) The BMPR2 production promoter according to claim 1, which promotes BMPR2 production in vascular endothelial cells. (3) A composition for improving or preventing pulmonary arterial hypertension, comprising the BMPR2 production promoter according to claim 1 or 2. Effect of the Invention
[0012] The ε-aminocaproic acid and / or a salt thereof of the present invention exhibited excellent BMPR2 production promoting effects. Furthermore, a BMPR2 production promoter and a pulmonary arterial hypertension improving agent that contain this pharmaceutical composition were safe and exhibited excellent pulmonary arterial hypertension improving effects. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] The ε-aminocaproic acid in the present invention is a synthetic plasmin inhibitor having a structure similar to the natural amino acid lysine, and is also known as aminocaproic acid, 6-aminohexanoic acid, or 6-aminocaproic acid.
[0014] Commercially available ε-aminocaproic acid and / or a salt thereof may be used, but it can also be produced by hydroformylating 3-pentenenitrile to produce 3-, 4-, and 5-formylvaleronitrile (FVN mixture), oxidizing the FVN mixture to produce 3-, 4-, and 5-cyanovaleric acid, hydrogenating the resulting product to produce 6-aminocaproic acid, 5-amino-4-methylvaleric acid, and 4-amino-3-ethylbutyric acid, and isolating 6-aminocaproic acid from the reaction product (JP Patent Publication No. 2004-513933).
[0015] Examples of salts of ε-aminocaproic acid include salts with alkali metals such as sodium, potassium, and lithium; salts with alkaline earth metals such as calcium and magnesium; salts with ammonium and amines such as monoethanolamine, diethanolamine, triethanolamine, triethylamine, piperazine, and arginine; and hydrochlorides. These can be produced from ε-aminocaproic acid by a conventional method.
[0016] In the present invention, BMPR2 is a member of the bone morphogenetic protein (BMP) receptor family of transmembrane serine-threonine kinases, and is also known as bone morphogenetic protein receptor 2, bone morphogenetic protein receptor type II, bone morphogenetic protein receptor type 2, bone morphogenetic protein type II receptor, BMR2, PPH1, BMPR3, BRK-3, POVD1, T-ALK, and BMPR-II.
[0017] The vascular endothelial cells of the present invention are cells that cover the lumen of blood vessels in a single layer.
[0018] Pulmonary arterial hypertension in the present invention refers to a condition in which the blood pressure in the pulmonary artery rises abnormally. As the condition progresses, symptoms such as shortness of breath during physical activity appear. In some cases, the condition is discovered due to other symptoms such as swelling of the face and legs, sudden fainting, etc.
[0019] The dosage of ε-aminocaproic acid and / or a salt thereof in the present invention is usually 1 mg to 2,000 mg per day.
[0020] The present invention can be used as a medicine, quasi-drug, or food. Examples of the form of the medicine include powder, tablet, granule, capsule, lozenge, oral liquid, suspension, and syrup. Examples of the form of the quasi-drug or food include, in addition to the above-mentioned pharmaceutical forms, confectionery such as biscuits, cookies, candy, and chocolate, seasonings such as vinegar, soy sauce, and dressing, meat products such as ham, bacon, and sausage, fish paste products such as kamaboko and hanpei, beverages such as fruit juice drinks, soft drinks, and alcoholic beverages, bread, koji, jam, and the like. All of these medicines, quasi-drugs, and foods are in a form that allows ε-aminocaproic acid and / or a salt thereof to be ingested at 1 mg to 2,000 mg / day, but tablets, granules, capsules, lozenges, oral liquid, and beverages, which are easy to adjust the intake amount, are more preferable. In addition, in producing pharmaceuticals, quasi-drugs, and foods, auxiliary substances commonly used in the technical fields of pharmaceuticals, quasi-drugs, and foods, such as excipients, binders, lubricants, flavorings, stabilizers, vitamins, minerals, and fragrances, can be used as necessary.
[0021] In the following, in order to explain the present invention in detail, formulation examples and experimental examples of the extract used in the present invention are given as examples, but the present invention is not limited thereto. EXAMPLES
[0022] The ε-aminocaproic acid and / or a salt thereof of the present invention can be formulated into the following formulations, as examples of formulations.
[0023] Formulation example 1: Beverages Formulation Content (g) 1. ε-aminocaproic acid 0.1 2. Citric acid 0.7 3. Fructose glucose liquid sugar 60.0 4.Fragrance 0.1 5.Purified water 39.1 Total 100.0 [Manufacturing method] Add ingredients 1 to 4 to ingredient 5, stir to dissolve, filter, heat sterilize, and fill into a 50ml glass bottle. By consuming one bottle of this beverage per day, you can consume 50mg of ε-aminocaproic acid per day.
[0024] Formulation Example 2: Tablets Formulation Content (g) 1. Sodium ε-aminocaproate 5.0 2. Corn starch 10.0 3. Refined white sugar 20.0 4. Calcium carboxymethylcellulose 10.0 5. Microcrystalline cellulose 40.0 6. Polyvinylpyrrolidone 5.0 7. Talc 10.0 Total 100.0 [Manufacturing method] Components 1 to 5 are mixed, then an aqueous solution of component 6 is added as a binder, and the mixture is granulated by a conventional method. Component 7 is added as a lubricant, and the mixture is compressed into tablets of 100 mg each. By taking 12 tablets per day, 60 mg of sodium ε-aminocaproate can be taken per day.
[0025] Formulation Example 3 Capsules Formulation Content (g) 1. ε-aminocaproic acid 5.0 2. Microcrystalline cellulose 60.0 3. Corn starch 15.0 4.Lactose 18.0 5. Polyvinylpyrrolidone 2.0 Total 100.0 [Manufacturing method] After mixing and granulating ingredients 1 to 5, fill 250 mg into a No. 2 hard capsule to obtain capsules. By taking 6 capsules per day, you can take in 75 mg of ε-aminocaproic acid per day.
[0026] Prescription Example 4 Powder Formulation Content (g) 1. Sodium ε-aminocaproate 5.0 2. Microcrystalline cellulose 40.0 3. Corn starch 55.0 Total 100.0 [Manufacturing method] Mix ingredients 1 to 3 and obtain a powder by a conventional method. By taking 1 g of the granules per day, you can take in 50 mg of sodium ε-aminocaproate per day.
[0027] Prescription Example 5 Tablets Formulation Content (g) 1. ε-aminocaproic acid 1.0 2.Dry cornstarch 50.0 3. Erythritol 40.0 4. Citric Acid 5.0 5. Sucrose fatty acid ester 3.0 6.Fragrance 1.0 Total 100.0 [Manufacturing method] Add an appropriate amount of purified water to ingredients 1 to 4, knead, extrude and granulate, then dry to obtain granules. Add ingredients 5 and 6 to the granules and compress to obtain tablets of 1g each. By taking 6 tablets a day, you can take in 60mg of ε-aminocaproic acid per day.
[0028] Next, experimental examples will be given to explain the effects of the present invention in detail.
[0029] Experimental Example 1 Effect of ε-aminocaproic acid and / or its salts on the expression of the gene encoding BMPR2 protein in human vascular endothelial cells The expression level of BMPR2 mRNA was measured. Human vascular endothelial cells (HUVEC) were seeded in a 6-well plate and cultured in HuMedia-EG2 (Kurabo) medium at 37°C and 5% CO2. When the cells were confluent, ε-aminocaproic acid was added to the cells at a concentration of 10 μM, which had been dissolved in HuMedia-EG2. Total RNA was extracted 24 hours after the addition. Total RNA was extracted from the cells using RNAiso Plus (Takara Bio), and the amount of total RNA was determined by absorbance at 260 nm using a spectrophotometer (NanoDrop). The expression level of mRNA was measured by real-time RT-PCR based on the total RNA extracted from the cells. For real-time RT-PCR, High Capacity RNA-to-cDNA Kit (Applied Biosystems) and SYBR Select Master Mix (Applied Biosystems) were used. That is, 500 ng of total RNA was subjected to reverse transcription reaction, followed by PCR reaction (95°C: 15 seconds, 60°C: 60 seconds, 40 cycles). Other procedures were performed according to the prescribed method, and the expression level of BMPR2 mRNA was calculated as a ratio to the expression level of β-actin mRNA, which is an internal standard. The BMPR2 expression promotion rate was calculated as the ratio of the expression level of BMPR2 mRNA in the sample addition group to the expression level of BMPR2 mRNA in the control (no sample addition) group. The primers used to measure the expression level of each gene are as follows.
[0030] Primer set for BMPR2 AACACCACTCAGTCCACCTC (SEQ ID NO: 1) TCTCCTGTCAACATTCTGTATCC (SEQ ID NO: 2) Primer set for β-actin CACTCTTCCAGCCTTCCTTCC (SEQ ID NO: 3) GTGTTGGCGTACAGGTCTTTG (SEQ ID NO: 4)
[0031] As a result, the expression level of BMPR2 mRNA in human vascular endothelial cells was increased by 14% by ε-aminocaproic acid compared to the control group. Therefore, ε-aminocaproic acid and / or its salts were found to have an effect of promoting BMPR2 production. Similar effects were also observed for various salts of ε-aminocaproic acid. [Industrial Applicability]
[0032] The BMPR2 production promoter and pulmonary arterial hypertension ameliorating agent according to the present invention, which are characterized by containing ε-aminocaproic acid and / or a salt thereof as an active ingredient, exhibit excellent ameliorating effects for the intended purposes of each agent, and therefore it is possible to provide medicines, quasi-drugs, and foods for the purpose of ameliorating pulmonary arterial hypertension.
Claims
1. A BMPR2 production promoter comprising ε-aminocaproic acid and / or a salt thereof.
2. The BMPR2 production promoter according to claim 1, which promotes BMPR2 production in vascular endothelial cells.
Citation Information
Patent Citations
DENTIFRICE COMPOSITION AND DISCOLORATION PREVENTING METHOD FOR DENTIFRICE COMPOSITION CONTAINING epsilon-AMINOCAPROIC ACID AND / OR TRANEXAMIC ACID
JP2006182655A
Shear-mediated controlled release for stenotic lesions and thrombolytic therapy
JP2013536848A
Combined compositions for treating alzheimer's disease and related disorders using zonisamide and acamprosate
JP2014205697A
Novel therapeutic approaches for treating alzheimer's disease
JP2015157841A
Methods and reagents for detecting fibrinolysis and increased fibrinolysis
JP2017520757A
